Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase- dependent DC functions and regulates experimental graft-versus-host disease in mice

Pavan Reddy, Yaping Sun, Tomomi Toubai, Raimon Duran-Struuck, Shawn G. Clouthier, Elizabeth Weisiger, Yoshinobu Maeda, Isao Tawara, Oleg Krijanovski, Erin Gatza, Chen Liu, Chelsea Malter, Paolo Mascagni, Charles A. Dinarello, James L M Ferrara

Research output: Contribution to journalArticle

217 Citations (Scopus)

Abstract

Histone deacetylase (HDAC) inhibitors are antitumor agents that also have antiinflammatory properties. However, the mechanisms of their immunomodulatory functions are not known. We investigated the mechanisms of action of 2 HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) and ITF 2357, on mouse DC responses. Pretreatment of DCs with HDAC inhibitors significantly reduced TLR-induced secretion of proinflammatory cytokines, suppressed the expression of CD40 and CD80, and reduced the in vitro and in vivo allostimulatory responses induced by the DCs. In addition, injection of DCs treated ex vivo with HDAC inhibitors reduced experimental graft-versus-host disease (GVHD) in a murine allogeneic BM transplantation model. Exposure of DCs to HDAC inhibitors increased expression of indoleamine 2,3-dioxygenase (IDO), a suppressor of DC function. Blockade of IDO in WT DCs with siRNA and with DCs from IDO-deficient animals caused substantial reversal of HDAC inhibition-induced in vitro suppression of DC-stimulated responses. Direct injection of HDAC inhibitors early after allogeneic BM transplantation to chimeric animals whose BM-derived cells lacked IDO failed to protect from GVHD, demonstrating an in vivo functional role for IDO. Together, these data show that HDAC inhibitors regulate multiple DC functions through the induction of IDO and suggest that they may represent a novel class of agents to treat immune-mediated diseases.

Original languageEnglish
Pages (from-to)2562-2573
Number of pages12
JournalJournal of Clinical Investigation
Volume118
Issue number7
DOIs
Publication statusPublished - Jul 1 2008
Externally publishedYes

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Histone Deacetylase Inhibitors
Histone Deacetylases
Graft vs Host Disease
Homologous Transplantation
Injections
Immune System Diseases
Antineoplastic Agents
Small Interfering RNA
Anti-Inflammatory Agents
Cytokines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase- dependent DC functions and regulates experimental graft-versus-host disease in mice. / Reddy, Pavan; Sun, Yaping; Toubai, Tomomi; Duran-Struuck, Raimon; Clouthier, Shawn G.; Weisiger, Elizabeth; Maeda, Yoshinobu; Tawara, Isao; Krijanovski, Oleg; Gatza, Erin; Liu, Chen; Malter, Chelsea; Mascagni, Paolo; Dinarello, Charles A.; Ferrara, James L M.

In: Journal of Clinical Investigation, Vol. 118, No. 7, 01.07.2008, p. 2562-2573.

Research output: Contribution to journalArticle

Reddy, P, Sun, Y, Toubai, T, Duran-Struuck, R, Clouthier, SG, Weisiger, E, Maeda, Y, Tawara, I, Krijanovski, O, Gatza, E, Liu, C, Malter, C, Mascagni, P, Dinarello, CA & Ferrara, JLM 2008, 'Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase- dependent DC functions and regulates experimental graft-versus-host disease in mice', Journal of Clinical Investigation, vol. 118, no. 7, pp. 2562-2573. https://doi.org/10.1172/JC134712
Reddy, Pavan ; Sun, Yaping ; Toubai, Tomomi ; Duran-Struuck, Raimon ; Clouthier, Shawn G. ; Weisiger, Elizabeth ; Maeda, Yoshinobu ; Tawara, Isao ; Krijanovski, Oleg ; Gatza, Erin ; Liu, Chen ; Malter, Chelsea ; Mascagni, Paolo ; Dinarello, Charles A. ; Ferrara, James L M. / Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase- dependent DC functions and regulates experimental graft-versus-host disease in mice. In: Journal of Clinical Investigation. 2008 ; Vol. 118, No. 7. pp. 2562-2573.
@article{1aa76b4050e0411c97fe38a744ef6400,
title = "Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase- dependent DC functions and regulates experimental graft-versus-host disease in mice",
abstract = "Histone deacetylase (HDAC) inhibitors are antitumor agents that also have antiinflammatory properties. However, the mechanisms of their immunomodulatory functions are not known. We investigated the mechanisms of action of 2 HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) and ITF 2357, on mouse DC responses. Pretreatment of DCs with HDAC inhibitors significantly reduced TLR-induced secretion of proinflammatory cytokines, suppressed the expression of CD40 and CD80, and reduced the in vitro and in vivo allostimulatory responses induced by the DCs. In addition, injection of DCs treated ex vivo with HDAC inhibitors reduced experimental graft-versus-host disease (GVHD) in a murine allogeneic BM transplantation model. Exposure of DCs to HDAC inhibitors increased expression of indoleamine 2,3-dioxygenase (IDO), a suppressor of DC function. Blockade of IDO in WT DCs with siRNA and with DCs from IDO-deficient animals caused substantial reversal of HDAC inhibition-induced in vitro suppression of DC-stimulated responses. Direct injection of HDAC inhibitors early after allogeneic BM transplantation to chimeric animals whose BM-derived cells lacked IDO failed to protect from GVHD, demonstrating an in vivo functional role for IDO. Together, these data show that HDAC inhibitors regulate multiple DC functions through the induction of IDO and suggest that they may represent a novel class of agents to treat immune-mediated diseases.",
author = "Pavan Reddy and Yaping Sun and Tomomi Toubai and Raimon Duran-Struuck and Clouthier, {Shawn G.} and Elizabeth Weisiger and Yoshinobu Maeda and Isao Tawara and Oleg Krijanovski and Erin Gatza and Chen Liu and Chelsea Malter and Paolo Mascagni and Dinarello, {Charles A.} and Ferrara, {James L M}",
year = "2008",
month = "7",
day = "1",
doi = "10.1172/JC134712",
language = "English",
volume = "118",
pages = "2562--2573",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "7",

}

TY - JOUR

T1 - Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase- dependent DC functions and regulates experimental graft-versus-host disease in mice

AU - Reddy, Pavan

AU - Sun, Yaping

AU - Toubai, Tomomi

AU - Duran-Struuck, Raimon

AU - Clouthier, Shawn G.

AU - Weisiger, Elizabeth

AU - Maeda, Yoshinobu

AU - Tawara, Isao

AU - Krijanovski, Oleg

AU - Gatza, Erin

AU - Liu, Chen

AU - Malter, Chelsea

AU - Mascagni, Paolo

AU - Dinarello, Charles A.

AU - Ferrara, James L M

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Histone deacetylase (HDAC) inhibitors are antitumor agents that also have antiinflammatory properties. However, the mechanisms of their immunomodulatory functions are not known. We investigated the mechanisms of action of 2 HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) and ITF 2357, on mouse DC responses. Pretreatment of DCs with HDAC inhibitors significantly reduced TLR-induced secretion of proinflammatory cytokines, suppressed the expression of CD40 and CD80, and reduced the in vitro and in vivo allostimulatory responses induced by the DCs. In addition, injection of DCs treated ex vivo with HDAC inhibitors reduced experimental graft-versus-host disease (GVHD) in a murine allogeneic BM transplantation model. Exposure of DCs to HDAC inhibitors increased expression of indoleamine 2,3-dioxygenase (IDO), a suppressor of DC function. Blockade of IDO in WT DCs with siRNA and with DCs from IDO-deficient animals caused substantial reversal of HDAC inhibition-induced in vitro suppression of DC-stimulated responses. Direct injection of HDAC inhibitors early after allogeneic BM transplantation to chimeric animals whose BM-derived cells lacked IDO failed to protect from GVHD, demonstrating an in vivo functional role for IDO. Together, these data show that HDAC inhibitors regulate multiple DC functions through the induction of IDO and suggest that they may represent a novel class of agents to treat immune-mediated diseases.

AB - Histone deacetylase (HDAC) inhibitors are antitumor agents that also have antiinflammatory properties. However, the mechanisms of their immunomodulatory functions are not known. We investigated the mechanisms of action of 2 HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) and ITF 2357, on mouse DC responses. Pretreatment of DCs with HDAC inhibitors significantly reduced TLR-induced secretion of proinflammatory cytokines, suppressed the expression of CD40 and CD80, and reduced the in vitro and in vivo allostimulatory responses induced by the DCs. In addition, injection of DCs treated ex vivo with HDAC inhibitors reduced experimental graft-versus-host disease (GVHD) in a murine allogeneic BM transplantation model. Exposure of DCs to HDAC inhibitors increased expression of indoleamine 2,3-dioxygenase (IDO), a suppressor of DC function. Blockade of IDO in WT DCs with siRNA and with DCs from IDO-deficient animals caused substantial reversal of HDAC inhibition-induced in vitro suppression of DC-stimulated responses. Direct injection of HDAC inhibitors early after allogeneic BM transplantation to chimeric animals whose BM-derived cells lacked IDO failed to protect from GVHD, demonstrating an in vivo functional role for IDO. Together, these data show that HDAC inhibitors regulate multiple DC functions through the induction of IDO and suggest that they may represent a novel class of agents to treat immune-mediated diseases.

UR - http://www.scopus.com/inward/record.url?scp=46749144173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46749144173&partnerID=8YFLogxK

U2 - 10.1172/JC134712

DO - 10.1172/JC134712

M3 - Article

VL - 118

SP - 2562

EP - 2573

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 7

ER -